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ABSTRACT The precise mechanism by which insulin is
degraded in mammalian cells is not presently known. Several
lines of evidence suggest that degradation is initiated by a
specific nonlysosomal insulin-degrading enzyme (IDE). The
potential importance of this insulin protease is illustrated by the
fact that there is an IDE in Drosophila melanogaster Kc cells
that shares both physical and kinetic properties with its
mammalian counterpart. We now demonstrate that the IDE is
present in other Drosophila cell lines and in the embryo, the
larvae, the pupae, and adult tissues of the fruit fly. Further, the
level of the IDE is developmentally regulated, being barely
detectable in the embryo but elevated 5-fold in the larvae and
pupae and =10-fold in the adult fly. The IDE levels in the cell
lines are particularly high, at least 10-fold greater than in the
adult fly. Analysis of Schneider L3 cells indicates that the
addition of the Drosophila hormone ecdysone, which induces
differentiation of the cells, causes a small but reproducible
increase in the level of the IDE and the insulin-degrading
activity. These results demonstrate that the IDE is evolution-
arily conserved and that its expression is tightly regulated
during differentiation ofDrosophila . The particular pattern of
developmental regulation suggests that the IDE plays a specific
and critical role in the later stages of the life cycle of the fly.
Although insulin is one of the best characterized effectors of
cell growth and metabolism, many aspects of its action need
to be clarified. In particular, the questions of how insulin is
degraded in the cell and of whether degradation of insulin
plays a critical regulatory role in insulin action have not yet
been resolved. Although lysosomal degradation may account
in part for insulin breakdown (1, 2), a nonlysosomal insulin-
degrading enzyme [IDE, formerly termed dplOO (3)] has been
characterized that cleaves insulin at sites corresponding to
the physiological degradation sites of insulin (4, 5) and
appears to influence cellular insulin degradation in vivo (6).
Identification and characterization of a nonmammalian ho-
mologue of the IDE would provide valuable evidence for
establishing the importance and functional role of this en-
zyme in cell growth and metabolism.
The insulin system has been highly conserved during
evolution. Insulin-like molecules have been isolated in var-
ious invertebrates such as Drosophila and are active in
bioassays developed for the mammalian systems (7, 8).
Homologues for the insulin receptor have also been identified
in Drosophila (9, 10). We have purified and characterized a
nonlysosomal IDE from a Drosophila cell line that has both
physical and kinetic properties that are strikingly similar to
those of its mammalian counterpart (11).
The IDE has a number of interesting properties that
suggest it might play an important role in growth and
development. In addition to recognizing insulin and insulin-
like growth factors, the Drosophila and mammalian enzymes
bind transforming growth factor type a (TGF-a) with rela-
tively high affinity (refs. 3 and 12 and unpublished data).
Since Drosophila is a powerful system for studying differen-
tiation, we determined the expression of the IDE in various
Drosophila cell lines and during different stages of Dro-
sophila development. At least three criteria for assessment of
IDE levels were used: affinity labeling of the enzyme, assay
of insulin-degrading activity, and immunoblotting with anti-
serum against the purified Drosophila IDE. The results
indicate that the IDE is widely distributed in Drosophila, and
the specific developmental profile favors an active role for
the IDE in the more differentiated stages of the organism's
life cycle.
METHODS
Materials and Cells. The Drosophila Schneider line 3 cells,
obtained from M. Pardue (Massachusetts Institute of Tech-
nology, Cambridge, MA), were grown in a gassed (5.5%
C02/94.5% air) humidified atmosphere at 250C in revised
Schneider medium (GIBCO) containing 10% (vol/vol) heat-
inactivated fetal bovine serum. The Drosophila Kc cells,
obtained from the Massachusetts Institute of Technology
Cell Culture Center, were grown at 250C in D22 medium (17)
supplemented with yeast hydrolysate. The Drosophila flies
were grown at 250C. Insulin and epidermal growth factor
(EGF) were purchased from Biomedical Technologies
(Stoughton, MA). The monoiodinated 1251I-labeled insulin
used for degradation assays was purchased from New En-
gland Nuclear. The recombinant TGF-a was a gift from R.
Derynck (Genentech, South San Francisco). Enzymobeads
were from Bio-Rad, and ecdysterone was from Behring
Diagnostics (San Diego, CA). Insulin and TGF-a were
iodinated by using Enzymobeads as described (3) (final
specific activity, 100 ,uCi/mg; 1 Ci = 37 GBq).
Immunoprecipitation and Affinity Labeling. Immuno-
precipitation was performed with a 1:10 dilution of the
anti-EGF receptor antiserum in 50 mM Hepes (pH 7.5)
overnight at 40C, and affinity labeling under saturating
conditions with either 1251I-labeled insulin or 1251I-labeled
TGF-a (10 ng) was as described (3, 12).
Ecdysone-Induced Differentiation of Schneider L3 Cells.
Growing Schneider cells were diluted to 3 x 106 cells per ml
and allowed to grow for 1 day before ecdysterone was added
to a final concentration of 1 ,uM. The number, viability, and
morphology of the cells in culture were monitored daily.
Abbreviations: IDE, insulin-degrading enzyme; TGF-a, transform-
ing growth factor type a; EGF, epidermal growth factor.
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Preparation of Cell Extracts. Cells were washed twice with
phosphate-buffered saline containing 10 mM glucose, 0.1 M
sucrose, 1.2 mM Mg SO4, 1.2 mM Mg Cl2, and 1 mM CaCI2
and lysed in 50 mM Hepes (pH 7.5), 10% (vol/vol) glycerol,
plus 1% Triton X-100 for 1 hr at 40C. The debris was removed
by centrifugation in a Microfuge for 10 min. The protein
concentration was estimated by the method of Bradford (13).
Preparation of Extracts from Staged Drosophila. Staged
Drosophila were washed extensively with Ringer's solution
(18), frozen, ground in a mortar, resuspended in hypotonic
solution, and homogenized as described by Thompson et al.
(12) for the Kc cell line.
'I2S-Insulin Degradation Assay. Aliquots of the Drosophila
extracts were diluted into a buffer containing 50 nM insulin,
bovine serum albumin (0.5 mg/ml), 100 mM sodium phos-
phate (pH 7.2), and 25,000 cpm of monoiodinated insulin
(specific activity, 80-120 ttCi/ttg). The samples were incu-
bated for 15 min at 370C, and the incubation was stopped by
the addition of cold 25% (wt/vol) trichloroacetic acid. The
relative amount of released radioactivity in the soluble
fraction was determined as described (11). The extent of
specific degradation was evaluated by adding an excess of
unlabeled insulin to parallel samples. All concentrations were
chosen so that the extent of insulin degradation was linear
with time and protein concentration.
Immunoblotting Analysis. The extracts were separated by
NaDodSO4/polyacrylamide gel electrophoresis on a 6.5%
gel. The samples were then electrophoretically transferred
from the gel to nitrocellulose, and the blot was probed with
an anti-IDE antibody as described (12). The anti-IDE anti-
body was prepared by excision of the purified IDE from a
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polyacrylamide gel and injection of the gel band into a rabbit.
The resultant polyclonal antiserum was shown by immuno-
blotting to bind specifically to the IDE in crude Kc cell
extracts and purified enzyme preparations (J.V.G. and
M.R.R., unpublished results).
RESULTS
We have described an IDE from Drosophila Kc cells (11) that
specifically binds insulin, TGF-a, and related factors (ref. 3
and unpublished data) and crossreacts with an anti-human
EGF receptor antibody (3, 12). This crossreactivity appears
to be specific to a particular anti-EGF receptor antibody
preparation and does not extend to the mammalian IDE. The
Drosophila 110-kDa protein is able to degrade porcine insulin
(11) and, like its mammalian counterpart, is found primarily
in the cytoplasm of cells (3). The distinctive binding and
antigenic properties of the Drosophila IDE were used as the
initial criteria for identifying the enzyme and determining its
distribution in various cell lines and at various stages of
development.
The Drosophila IDE was readily detected in all other
Drosophila cell lines tested. To visualize the Drosophila IDE,
total cell extracts were concentrated by immunoprecipitation
with the anti-EGF receptor antibody and then affinity labeled
with 1251I-labeled insulin. The results obtained for the Schnei-
der line 3 (Fig. 1) revealed a 110-kDa band that was specif-
ically immunoprecipitated and labeled with 1251I-labeled in-
sulin. Both unlabeled insulin and EGF were able to compete
with the labeled insulin for binding, and no immunoprecipi-
tation of this band was detected when preimmune serum was
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FIG. 1. Autoradiograph of the IDE isolated from cell lines and various developmental stages of D. melanogaster. Schneider L3 cells (50 ,ug
of total cell extracts) were immunoprecipitated with preimmune serum (lane 1) or with anti-EGF receptor antiserum (lanes 2-4) and subsequently
labeled with "25I-labeled insulin in the absence (lanes 1 and 2) or in the presence of excess unlabeled insulin (lane 3) or EGF (lane 4). Embryos
[400 ,ug of cytoplasmic (lanes 5-8) or 800 ,ug of membrane (lane 9) extracts from 0- to 24-hr embryos] were immunoprecipitated with preimmune
serum (lane 5) or with an anti-EGF receptor antibody (lanes 6-9) and subsequently labeled with 125I-labeled insulin in the absence (lanes 5, 6,
and 9) or in the presence of excess of unlabeled insulin (lane 7) or EGF (lane 8). Larvae [200 ,sg of cytoplasmic (lanes 10-13) or 500 ,ug of
membrane (lane 14) extracts from first, second, and third instar larvae] were immunoprecipitated with preimmune serum (lane 10) or anti-EGF
receptor antiserum (lanes 11-14) and subsequently labeled with 125I-labeled insulin in the absence (lanes 10, 11, and 14) or in the presence of
excess unlabeled insulin (lane 12) or EGF (lane 13). Adult heads [400 gg of cytoplasmic (lanes 15-18) or 500 ;Lg of membrane (lane 19) extracts
from adult fly heads] were immunoprecipitated with preimmune serum (lane 15) or with anti-EGF receptor antiserum (lanes 16-19) and
subsequently labeled with 125I-labeled insulin in the absence (lanes 15, 16, and 19) or in the presence of excess unlabeled insulin (lane 17) or
EGF (lane 18). Adult bodies (400 ,ug of cytoplasmic extracts from bodies of adult flies) were immunoprecipitated with preimmune serum (lane
20) or anti-EGF receptor antiserum (lanes 21-23) and subsequently labeled in the absence (lanes 20 and 21) or in the presence of excess unlabeled
insulin (lane 22) or EGF (lane 23). Adult/Kc cells [a mixture of total extracts from adult flies (1 mg) and Kc cells (0.5 mg)] were incubated with
125I-labeled TGF-a in the absence (lanes 24 and 26) or in the presence (lanes 25 and 27) of excess unlabeled insulin. All samples were then
crosslinked and analyzed by NaDodSO4/PAGE. The molecular mass of the IDE is 110 kDa.
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used. Similar results were obtained for the Drosophila
melanogaster Schneider L2 and the Drosophila hydei line 15
cells (data not shown).
The ubiquitous distribution of the Drosophila IDE became
apparent when various developmental stages of the fly were
examined (Fig. 1). Cytoplasmic extracts of embryo, larvae,
and adult bodies and heads contained a 110-kDa protein
corresponding to the IDE that was immunoprecipitated by
the anti-EGF receptor antibody and was specifically labeled
by 125I-labeled insulin. Similar results were obtained for the
pupae (data not shown). As in the case ofKc cells (3), the IDE
was also detected in membrane fractions of these organisms,
but the relative amount was low compared to that in the
cytoplasmic fractions. The specific binding of the IDE to
1251-labeled TGF-a in adult fly and Kc cell extracts is also
illustrated in Fig. 1. On the basis of binding specificity,
molecular weight, and crossreactivity with the anti-EGF
receptor antibody, the IDE identified in the intact fly appears
to be the same as that characterized from the Drosophila Kc
cell line.
The observations that the IDE is highly conserved between
Drosophila and mammals and that its ability to degrade
insulin is inhibited by other growth factors suggest that the
enzyme might be a target for regulation during the develop-
mental process. To explore this possibility, we initially
determined the levels of the IDE in D. melanogaster
Schneider L3 cells, which are induced to differentiate by the
molting hormone ecdysterone (14). Upon exposure to ecdy-
sterone, the L3 cells stop growing and change morphology;
at the same time there is an increase in the overall protein
synthesis. This effect is illustrated in Fig. 2 C and D. When
the level of the Drosophila IDE in ecdysterone-treated cells
was examined as described above, a small but significant
increase of 2-fold over background protein levels was de-
tected (Fig. 2 B and D). Actin levels, in contrast, decreased
over the same time period (Fig. 2E). When insulin-degrading
activity was examined directly in the cell extracts by a
trichloroacetic acid precipitation assay (11), a similar pattern
of induction by the hormone was noted (Fig. 3). These results
suggest that the IDE can be specifically regulated in the
course of differentiation.
To determine the pattern of expression of the IDE during
development, the level of the IDE was quantitated in samples
from various stages of Drosophila development. When the
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FIG. 2. Ecdysone induces an increase in the level of the IDE in Schneider L3 cells. (A) Cell growth and viability of L3 cells after ecdysone
treatment. Growing L3 cells were incubated in the absence (0, A) or presence (o, A) of 1 .M ecdysone for the indicated times at 250C. The extent
of the ecdysone-induced differentiation was monitored by determining the increase in cell number (o, e), and the cell viability (A, A) was tested
by the trypan blue exclusion assay. (B) Autoradiograph depicting the time course of ecdysone-induced changes in IDE expression. Cells were
treated with ecdysone for 1 day (lane 1), 2 days (lane 2), 3 days (lane 3), 4 days (lane 4), 5 days (lane 5), or 6 days (lane 6). (C-E) Ecdysone-treated
or control cells (5 x 104 cells per sample), as shown in A, were lysed at the times indicated, and the amount of the IDE was quantitated by
immunoprecipitation with an anti-EGF receptor antibody and affinity labeling with 125I-labeled insulin, both under saturating conditions. The
samples were then resolved by NaDodSO4/PAGE, and the IDE was quantitated by densitometric scanning of the autoradiograph. (C and D)
Time course of ecdysone-induced changes in the IDE. The amount of IDE was normalized to a constant cell number (C) or to a constant cell
protein concentration (mg) (D). Data are presented as% control. (E) Ecdysone-induced changes in actin. Total cell extracts containing equivalent
amounts of protein from ecdysone-treated cells and control cells were resolved by NaDodSO4/PAGE. The prominent 45-kDa actin band was
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FIG. 3. "25I-labeled insulin degradation in Schneider L3 cells after
ecdysone treatment. Total cell extracts prepared as in Fig. 2 were
also incubated with 1251-labeled insulin in the presence or in the
absence ofexcess unlabeled insulin to determine the extent of insulin
degradation. The data are plotted as % control. (A) Data are
normalized to cell number. (B) Data are normalized to mg of protein.
relative levels of the IDE were examined, after immuno-
precipitation with the anti-EGF receptor antibody and affin-
ity labeling with 1251I-labeled insulin under saturating condi-
tions, a gradual increase from the embryo to the adult was
observed (Fig. 4). To ensure that the results were quantitative
and that the IDE samples were not being selectively de-
graded, an internal exogenously labeled IDE standard was
added to a duplicate set of control organisms. Quantitation of
the 110-kDa IDE band indicated that the increase from
2 3 4 5
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FIG. 4. Autoradiograph illustrating the relative levels of IDE
from various stages of D. melanogaster development. Equivalent
amounts of protein of total extracts from embryo (lane 1), adult (lane
2), Kc cells (lane 3), or Kc cytoplasmic fraction (lane 4) were
subjected to immunoprecipitation with anti-EGF receptor antibody
and to labeling with l25l-labeled insulin under saturating conditions.
Lane 5 contains 251I-labeled insulin IDE that was used as an internal
standard to assess degradation. Lanes 6-8 contain the 1251I-labeled
IDE mixed with embryo, adult, and Kc extracts, respectively, and
immunoprecipitated in parallel incubations. Samples were analyzed
by NaDodSO4/PAGE. The molecular mass of the IDE is 110 kDa.
Table 1. Quantitation of Drosophila IDE in extracts from
various developmental stages and cell lines
Normalized "251-labeled Normalized insulin-
Source insulin binding degrading activity
Embryos 1.00 1.00
Larvae 5.53 ± 1.05 4.59 ± 1.66
Pupae 5.7 ± 1.24 4.1 ± 2.13
Adults 10.7 ± 0.78 8.06 ± 1.62
Kc cells 335 ± 50 23.3 ± 4.49
Samples were prepared as described in the legend to Fig. 4, and the
level of the IDE in the autoradiographs was quantitated by densi-
tometry. All results were normalized relative to the amount of
"25I-labeled insulin bound to the IDE in the embryo extract. Extracts
containing equivalent amounts of protein were prepared and ana-
lyzed for insulin degradation activity. All results were normalized
relative to the level of insulin-degrading activity in the embryo
extract.
embryo to larvae and pupae was -5-fold and the increase
from embryo to adult approached 10-fold (Table 1). No
difference was detected between the IDE protein levels in
early-stage embryos (0-8 hr) and late-stage embryos (8-24 or
12-20 hr). The Kc cell line, like the other Drosophila cell
lines, expressed unusually high levels ofthe protein (-30-fold
over the level in adult flies), raising the possibility that this
enzyme is required for maintaining the cells in culture.
This pattern of differentiation-enhanced expression was
confirmed when the IDE level was determined either by
direct insulin-degradation assays of the extracts (Table 1) or
by immunoblotting analysis of the samples (Fig. 5) with a
specific antibody directed against the purified IDE from Kc
cells (unpublished data). In both cases, a gradual increase in
the level of the IDE from the embryo to the adult stage was
observed, with the highest level detected in the Kc cell line.
Thus, the primary target of IDE action appears to be in the
most fully differentiated state.
DISCUSSION
We have demonstrated that a Drosophila IDE is a widely
distributed protein that is present in isolated Drosophila cell
lines and during the various stages of the organism's devel-
opment. The expression of the IDE is regulated in an
2 3 4 5 6 7 8




FIG. 5. Autoradiograph of immunoblot showing the relative
amounts of IDE present in the various Drosophila developmental
stages. Samples were probed with preimmune antisera (lanes 1-4) or
anti-Drosophila IDE antibody (lanes 5-8). Lanes: 1 and 7, 275 /.g of
extract from embryos; 2 and 6, 192 ug of extract from adult flies; 3
and 8, 54 Mug from Kc cells; 4 and 5, 275 ug of extract from embryos
mixed with purified IDE.
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ecdysone-induced cell line and in the intact fly. In both cases,
the level of the enzyme directly correlates with the extent of
differentiation. These observations, in conjunction with the
fact that the physical and kinetic properties of this enzyme
are highly conserved between mammals and Drosophila (11),
suggest that the IDE plays a discrete and important role in the
maintenance of the differentiated organism.
Since crude extracts of the cells and tissues were used, we
utilized at least three criteria for identifying and quantitating
the Drosophila insulin-degrading protein. The distinctive
features of this enzyme relate to the fact that the protein can
bind porcine insulin and human TGF-a with high affinity (Kd
100 nM and 1 nM, respectively) and can be isolated through
immunoprecipitation with an anti-EGF receptor antiserum
(3). Since this assay is more sensitive and more specific than
that of insulin degradation, this was the primary method used
for identification of the enzyme. We have also prepared a
specific antiserum against the purified enzyme that is very
effective in immunoblot analysis but less efficient at immu-
noprecipitating the native enzyme (unpublished data). There-
fore, this antiserum was used to verify the relative distribu-
tion of the IDE during the various stages of Drosophila
development.
The significance of the high level of expression of the IDE
in the Drosophila cell lines is not presently clear. Although
the slight elevation of the levels of the IDE in the differen-
tiating Drosophila cell line is consistent with the changes
observed in the intact organism, the tissue that the cell line
corresponds to is not known. The origin of the cell lines
assayed is embryonal, but the expression of the IDE in these
lines is an order of magnitude greater than that in the intact
embryo. Thus, it is possible that expression of the IDE is
required for establishment or maintenance of the cells in
culture. The fact that the IDE is present in fly heads and
bodies is consistent with the wide distribution of the IDE in
mammalian tissues (cf. ref. 15).
It is interesting to compare the developmental profile ofthe
IDE to the expression of the Drosophila homologues of the
insulin receptor. Rosen and colleagues (9, 10, 16) identified in
Drosophila a counterpart to the mammalian insulin receptor
that could be crosslinked to 125I-labeled insulin and reacted
with anti-human insulin receptor antisera. The molecular
mass of the insulin-bound a subunit present in both embry-
onal and adult Drosophila was 120-135 kDa (10, 16), similar
to that of the a subunit of the mammalian insulin receptor. An
insulin-binding a subunit of -100 kDa was also expressed
transiently in embryos (10) and correlated with the major
insulin-induced tyrosine kinase activity. Our results suggest
that the IDE may act in a coordinate fashion with the adult
Drosophila homologue of the mammalian insulin receptor in
the differentiated organism.
In summary, these findings indicate that the Drosophila
IDE, although ubiquitous, is under tightly regulated devel-
opmental control, suggesting that the enzyme acts at a
rate-limiting step and is either detrimental during periods of
rapid growth or only required during the later stages of
differentiation.
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